暫無數據
代碼股票名稱
最新價漲跌額漲跌幅成交量成交額今開昨收最高最低總市值流通市值總股本流通股本5日漲跌幅10日漲跌幅20日漲跌幅60日漲跌幅120日漲跌幅250日漲跌幅年初至今漲跌幅股息率TTM換手率市盈率TTM市盈率(靜)振幅所屬行業
美股期權個股詳情
SLS240517C500
- 0.95
- 0.000.00%
延時15分鐘行情收盤價 05/17 11:46 (美東)
0.95最高價0.95最低價
0.95今開0.95昨收1張成交量0張未平倉合約數0.50行權價0.00成交額0.00%引伸波幅-2.03%溢價2024/05/17到期日0.98内在价值100合約乘數-2天距到期日0.00時間價值100合約規模美式期權類型--Delta--Gamma1.56槓桿倍數--Theta--Rho--有效槓桿--Vega
分時
- 5日
- 日K
新聞
在反洗錢治療管道取得進展的情況下，SELLAS生命科學獲得強勁的買入評級
快訊 | SELLAS Life Sciences Gr 2024 年第一季度調整後每股收益 (0.21) 未達預期 (0.16) 美元
SELLAS 生命科學第一季度虧損/21c >SLS
SELLAS 生命科學第一季度虧損/21c >SLS
Sellas Life Sciences | 10-Q：季度報表
快訊 | Sellas 生命科學第一季度基本每股收益美元 -0.21
新聞稿：SELLAS Life Sciences公佈2024年第一季度財務業績並提供公司最新情況
SELLAS Life Sciences公佈2024年第一季度財務業績並提供公司最新情況——宣佈了獨立數據監測委員會（IDMC）關於延續第三階段REGAL的建議
評論
$Sellas Life Sciences(SLS.US$ I bought more. 🖕🩳🔥
7
$Sellas Life Sciences(SLS.US$
NEWS
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
SELLAS Life Sciences Group, Inc. announces positive Phase 2 preliminary data of SLS009 in relapsed/refractory acute myeloid leukemia (r/r AML), achieving a 100% response rate in patients with ASXL1 mutation at the optimal dose level. The company has filed IP protection related to the ASXL1 mutation, sh...
NEWS
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
SELLAS Life Sciences Group, Inc. announces positive Phase 2 preliminary data of SLS009 in relapsed/refractory acute myeloid leukemia (r/r AML), achieving a 100% response rate in patients with ASXL1 mutation at the optimal dose level. The company has filed IP protection related to the ASXL1 mutation, sh...
2
$Sellas Life Sciences(SLS.US$ Sellas Life Sciences Group Inc: Next Efficacy and Safety Assessment of All Regal Patients (N=127) in June 2024
2
$Sellas Life Sciences(SLS.US$ Sellas Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in Regal Phase 3 Study
閱讀更多